Vimarsana
Biggest News Aggregation in the World

Page 2 - Breaking Data News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Breaking Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Breaking Data Today - Breaking & Trending Today

Breaking Data (CVE:BKD) Stock Price Down 2.8% - Vimarsana News

Breaking Data (CVE:BKD) Stock Price Down 2.8%

Shares of Breaking Data Corp. (CVE:BKD – Get Free Report) dropped 2.8% during trading on Wednesday . The company traded as low as C$0.70 and last traded at C$0.70. Approximately 45,700 shares were traded during trading, a decline of 52% from the average daily volume of 94,594 shares. The stock had previously closed at C$0.72. […]

Breaking Data (CVE:BKD) Shares Down 2.8% - Vimarsana News

Breaking Data (CVE:BKD) Shares Down 2.8%

Shares of Breaking Data Corp. (CVE:BKD – Get Free Report) were down 2.8% during trading on Wednesday . The stock traded as low as C$0.70 and last traded at C$0.70. Approximately 45,700 shares traded hands during mid-day trading, a decline of 52% from the average daily volume of 94,594 shares. The stock had previously closed […]

Abbott Unveils Late-breaking Data Showing the World's First Dual-chamber Leadless Pacemaker Study Met All Three Primary Endpoints - Vimarsana News

Abbott Unveils Late-breaking Data Showing the World's First Dual-chamber Leadless Pacemaker Study Met All Three Primary Endpoints

Abbott's AVEIR DR i2i IDE study is the industry's first prospective study on the safety and performance of the world's first dual-chamber leadless pacemaker

Abbott Unveils Late-Breaking Data Showing the World's First Dual-Chamber Leadless Pacemaker Study Met All Three Primary Endpoints - Vimarsana News

Abbott Unveils Late-Breaking Data Showing the World's First Dual-Chamber Leadless Pacemaker Study Met All Three Primary Endpoints

Abbott (NYSE: ABT) today announced late-breaking results from the AVEIR™ dual-chamber (DR) i2i™ Investigational Device Exemption (IDE) study, a large-scale study to assess the world's first dual-chamber leadless pacemaker, showing that the leadless pacemaker met its three prespecified primary endpoints for safety ...

Abbott Unveils Late-Breaking Data Showing the World's First Dual-Chamber Leadless Pacemaker Study Met All Three Primary Endpoints - Vimarsana News

Abbott Unveils Late-Breaking Data Showing the World's First Dual-Chamber Leadless Pacemaker Study Met All Three Primary Endpoints

Abbott's AVEIR™ DR i2i™ IDE study is the industry's first prospective study on the safety and performance of the world's first dual-chamber leadless pacemakerThe study successfully met... | May 20, 2023